Scientia Pharmaceutica

ÖSTERREICHISCHE PHARMAZEUTISCHE GESELLSCHAFT

MDPI

Supplementary information

Voltammetric Behaviour of Drug Molecules as a Predictor of Metabolic Liabilities

Hikari Fuchigami [1], Mandeep K. Bal [2], Dale A. C. Brownson [2], Craig E. Banks [2] and Alan M. Jones [3,*]

[1] School of Biosciences, University of Birmingham, Edgbaston, B15 2TT, United Kingdom; HXF916@student.bham.ac.uk

[2] Manchester Metropolitan University, Faculty of Science and Engineering, Chester Street, Manchester, M1 5GD, United Kingdom; m.kaur@mmu.ac.uk (M.K.B.); D.Brownson@mmu.ac.uk (D.A.C.B.); C.Banks@mmu.ac.uk (C.E.B.)

[3] School of Pharmacy, University of Birmingham, Edgbaston, B15 2TT, United Kingdom

* Correspondence: a.m.jones.2@bham.ac.uk; Tel.: +44-01214-147-288

Received: 15 September 2020; Accepted: 3 October 2020; Published: date

CONTENTS

^{1}H and ^{13}C NMR spectra of synthesised and purchased drug molecules page 2-7

Figure S1. ^{1}H NMR spectrum of **2** (400 MHz, $CDCl_3$).



Figure S2. ^{13}C NMR spectrum of **2** (101 MHz, $CDCl_3$).



Figure S3. ^{1}H NMR spectrum of Propanidid 400 MHz, $CDCl_3$).



Figure S4. ^{13}C NMR spectrum of Propanidid (101 MHz, $CDCl_3$).



Figure S5. ^{1}H NMR spectrum of Entacapone (400 MHz, $CDCl_3$).



Figure S6. ^{1}H NMR spectrum of Lidocaine (400 MHz, $CDCl_3$).



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).